This decision follows the positive outcomes from the multicentre, open-label Phase II TRUST-I trial. The single-arm trial was instrumental in assessing the therapy’s tolerability, efficiency, and safety in
This strategic move involves a total payment of $18m and terminates prior agreements with VBI, including future milestone and royalty obligations. Under the terms of the agreement, Brii
As per the deal, WuXi Bio will offer comprehensive discovery services, including antibody generation, spearhead detection, optimisation, and developability assessment. These services will be supported by WuXi’s single
The new indication specifically targets unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ) expressing programmed death-ligand 1 (PD-L1). The approval for the
This collaboration aims to leverage Axcelead’s DegLead Platform, an integrated service solution designed for the next generation of small-molecule drug discovery, to support Astellas’ discovery efforts and contribute
A human monoclonal antibody, BAT2206 is currently undergoing regulatory review with several health authorities, including the China National Medical Products Administration (NMPA), the US Food and Drug Administration
BAL2420 is a lipooligosaccharide phosphoethanolamine transferase A (LptA) inhibitor, a new class of antibiotics with bactericidal activity against Gram-negative bacteria, including drug-resistant strains. The additional CARB-X funding is
The collaboration focuses on a three-asset portfolio of preclinical next-wave ADCs. These ADC assets were developed through a joint effort between WuXi Biologics and Hangzhou DAC Biotechnology, leveraging
With this investment, Gilead’s equity ownership in Assembly Bio has increased to 29.9%. These funds are expected to extend Assembly Bio’s cash runway to mid-2026 and will support
This follows orphan drug status granted by the US Food and Drug Administration (FDA) in November 2020. Currently, mitapivat is approved in the US under the brand name
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.